JP2012524771A5 - - Google Patents

Download PDF

Info

Publication number
JP2012524771A5
JP2012524771A5 JP2012506583A JP2012506583A JP2012524771A5 JP 2012524771 A5 JP2012524771 A5 JP 2012524771A5 JP 2012506583 A JP2012506583 A JP 2012506583A JP 2012506583 A JP2012506583 A JP 2012506583A JP 2012524771 A5 JP2012524771 A5 JP 2012524771A5
Authority
JP
Japan
Prior art keywords
oil
eur
composition
composition according
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012506583A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012524771A (ja
Filing date
Publication date
Priority claimed from PCT/GB2009/050416 external-priority patent/WO2010122276A1/en
Priority claimed from GB0906977A external-priority patent/GB2469792A/en
Application filed filed Critical
Priority claimed from PCT/GB2010/050671 external-priority patent/WO2010122355A1/en
Publication of JP2012524771A publication Critical patent/JP2012524771A/ja
Publication of JP2012524771A5 publication Critical patent/JP2012524771A5/ja
Pending legal-status Critical Current

Links

JP2012506583A 2009-04-23 2010-04-23 中性油を含む舌下用の医薬組成物 Pending JP2012524771A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/GB2009/050416 WO2010122276A1 (en) 2009-04-23 2009-04-23 Drug delivery
GBPCT/GB2009/050416 2009-04-23
GB0906977.4 2009-04-23
GB0906977A GB2469792A (en) 2009-04-23 2009-04-23 Oil-based pharmaceutical formulation for sublingual delivery
PCT/GB2010/050671 WO2010122355A1 (en) 2009-04-23 2010-04-23 Sublingual pharmaceutical composition comprising a neutral oil

Publications (2)

Publication Number Publication Date
JP2012524771A JP2012524771A (ja) 2012-10-18
JP2012524771A5 true JP2012524771A5 (https=) 2013-05-09

Family

ID=42236683

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012506583A Pending JP2012524771A (ja) 2009-04-23 2010-04-23 中性油を含む舌下用の医薬組成物

Country Status (15)

Country Link
US (1) US20120058158A1 (https=)
EP (1) EP2421503A1 (https=)
JP (1) JP2012524771A (https=)
CN (1) CN102458358A (https=)
AU (1) AU2010240653A1 (https=)
BR (1) BRPI1013539A2 (https=)
CA (1) CA2756879A1 (https=)
IL (1) IL215454A (https=)
MX (1) MX2011010835A (https=)
MY (1) MY167918A (https=)
NZ (1) NZ595467A (https=)
RU (1) RU2011139638A (https=)
SG (1) SG175160A1 (https=)
WO (1) WO2010122355A1 (https=)
ZA (1) ZA201107089B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
GB0720967D0 (en) * 2007-10-25 2007-12-05 Protophama Ltd Anti-material pharmaceutical composition
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
US20130254139A1 (en) * 2012-03-21 2013-09-26 Xiaoguang Lei Systems and methods for building a universal intelligent assistant with learning capabilities
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US10376586B2 (en) 2016-02-16 2019-08-13 Entourage Bioscience, LLC Method and compositions for solubilizing non-polar constituents
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
KR20230137362A (ko) * 2016-05-05 2023-10-04 어퀘스티브 테라퓨틱스, 아이엔씨. 강화된 전달 에프네프린 조성물
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
KR102442753B1 (ko) * 2016-12-26 2022-09-16 셀릭스 바이오 프라이빗 리미티드 만성 통증 치료를 위한 화합물
IL313551A (en) * 2017-09-27 2024-08-01 Aquestive Therapeutics Inc Enhanced delivery epinephrine and prodrug compositions
EP3902523A1 (en) 2018-12-29 2021-11-03 3M Innovative Properties Company Oral articles and methods of use
WO2020136606A1 (en) 2018-12-29 2020-07-02 3M Innovative Properties Company Oral articles and methods of use
HUE073311T2 (hu) * 2020-03-31 2026-01-28 Remicine Ip B V Hiperinflammatorikus szindróma kezelése
EP4422607A4 (en) 2021-10-25 2025-09-03 Aquestive Therapeutics Inc ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4869899A (en) * 1986-03-10 1989-09-26 Walter Burghart Pharmaceutical preparation and process for producing the same
US5955098A (en) * 1996-04-12 1999-09-21 Flemington Pharmaceutical Corp. Buccal non polar spray or capsule
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
DK1361864T3 (en) * 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
RU2432950C2 (ru) * 2006-01-25 2011-11-10 Инсис Терапьютикс Инк. Подъязычный спрей на основе фентанила
CA2698752A1 (en) * 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
GB0720967D0 (en) * 2007-10-25 2007-12-05 Protophama Ltd Anti-material pharmaceutical composition
NZ595469A (en) * 2009-04-23 2013-10-25 Londonpharma Ltd Sublingual spray formulation comprising dihydroartemesinin

Similar Documents

Publication Publication Date Title
JP2012524771A5 (https=)
RU2011139638A (ru) Сублингвальная фармацевтическая композиция, содержащая нейтральное масло
JP7250865B2 (ja) 固溶体組成物および心血管疾患における使用
JP2022174168A (ja) ω3脂肪酸の自己乳化組成物
NZ600720A (en) A Seamless Capsule For A Liquid Pharmaceutical Composition
JP2015520235A5 (https=)
JP2013508296A5 (https=)
JP2014509655A5 (https=)
KR20160032120A (ko) ω3 지방산의 자기 유화 조성물
Aggarwal et al. Natural oils as skin permeation enhancers for transdermal delivery of olanzapine: in vitro and in vivo evaluation
JP2015520236A5 (https=)
RU2014139008A (ru) Гормонсодержащая эмульсия, содержащая фосфолипиды криля
WO2009139589A3 (en) Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant
RU2017111503A (ru) КОМПОЗИЦИИ(17-β)-3-ОКСОАНДРОСТ-4-ЕН-17-ИЛ УНДЕКАНОАТА И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
WO2008120711A1 (ja) タミバロテンカプセル剤
RU2015102597A (ru) Липидные композиции рацекадотрила
Goswami et al. Permeation enhancer for TDDS from natural and synthetic sources: A review
GB2469754A (en) Sub-lingual drug delivery system using a neutral oil
CA2829015C (en) Formulation comprising phenylaminopyrimidine derivative as active agent
HRP20160446T1 (hr) Farmaceutski pripravci koji sadrže derivat kamptotecina
AR084235A1 (es) Composiciones farmaceuticas que comprenden alisporivir
HK1199396A1 (en) Oral complex formulation comprising omega-3 fatty acid and hmg-coa reductase inhibitor with improved stability
RU2011127248A (ru) Экструдаты с игловидными действующими веществами
JP2012524772A (ja) ジヒドロアルテミシニンを含む舌下スプレー用製剤
RU2015128028A (ru) Длинноцепочечные липосбалансированные сложные эфиры тестостерона для пероральной доставки